ERBB2 and breast cancer: The present literature review assesses the value of molecular testing in adjuvant treatment and predicting the prognosis of HR+/HER2- early-stage BC, available evidence supporting the application of these techniques in various patient groups, and the extent to which these methods facilitate informed therapeutic decisions.